These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 18543327)

  • 1. Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma: a phase 2 trial in the North Central Cancer Treatment Group.
    Ansell SM; Inwards DJ; Rowland KM; Flynn PJ; Morton RF; Moore DF; Kaufmann SH; Ghobrial I; Kurtin PJ; Maurer M; Allmer C; Witzig TE
    Cancer; 2008 Aug; 113(3):508-14. PubMed ID: 18543327
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of single-agent temsirolimus (CCI-779) for relapsed mantle cell lymphoma.
    Witzig TE; Geyer SM; Ghobrial I; Inwards DJ; Fonseca R; Kurtin P; Ansell SM; Luyun R; Flynn PJ; Morton RF; Dakhil SR; Gross H; Kaufmann SH
    J Clin Oncol; 2005 Aug; 23(23):5347-56. PubMed ID: 15983389
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase III study to evaluate temsirolimus compared with investigator's choice therapy for the treatment of relapsed or refractory mantle cell lymphoma.
    Hess G; Herbrecht R; Romaguera J; Verhoef G; Crump M; Gisselbrecht C; Laurell A; Offner F; Strahs A; Berkenblit A; Hanushevsky O; Clancy J; Hewes B; Moore L; Coiffier B
    J Clin Oncol; 2009 Aug; 27(23):3822-9. PubMed ID: 19581539
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical efficacy and management of temsirolimus in patients with relapsed or refractory mantle cell lymphoma.
    Coiffier B
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):351-9. PubMed ID: 23763923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.
    Dreyling M; Jurczak W; Jerkeman M; Silva RS; Rusconi C; Trneny M; Offner F; Caballero D; Joao C; Witzens-Harig M; Hess G; Bence-Bruckler I; Cho SG; Bothos J; Goldberg JD; Enny C; Traina S; Balasubramanian S; Bandyopadhyay N; Sun S; Vermeulen J; Rizo A; Rule S
    Lancet; 2016 Feb; 387(10020):770-8. PubMed ID: 26673811
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temsirolimus in mantle cell lymphoma and other non-Hodgkin lymphoma subtypes.
    Hess G; Smith SM; Berkenblit A; Coiffier B
    Semin Oncol; 2009 Dec; 36 Suppl 3():S37-45. PubMed ID: 19963099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A multicenter phase II trial (SAKK 36/06) of single-agent everolimus (RAD001) in patients with relapsed or refractory mantle cell lymphoma.
    Renner C; Zinzani PL; Gressin R; Klingbiel D; Dietrich PY; Hitz F; Bargetzi M; Mingrone W; Martinelli G; Trojan A; Bouabdallah K; Lohri A; Gyan E; Biaggi C; Cogliatti S; Bertoni F; Ghielmini M; Brauchli P; Ketterer N;
    Haematologica; 2012 Jul; 97(7):1085-91. PubMed ID: 22315486
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study.
    Ansell SM; Tang H; Kurtin PJ; Koenig PA; Inwards DJ; Shah K; Ziesmer SC; Feldman AL; Rao R; Gupta M; Erlichman C; Witzig TE
    Lancet Oncol; 2011 Apr; 12(4):361-8. PubMed ID: 21440503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of two doses of intravenous temsirolimus in patients with relapsed/refractory mantle cell lymphoma.
    Jurczak W; Ramanathan S; Giri P; Romano A; Mocikova H; Clancy J; Lechuga M; Casey M; Boni J; Giza A; Hess G
    Leuk Lymphoma; 2018 Mar; 59(3):670-678. PubMed ID: 28768446
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temsirolimus in the treatment of mantle cell lymphoma: frequency and management of adverse effects.
    Bouabdallah K; Ribrag V; Terriou L; Soria JC; Delarue R
    Curr Opin Oncol; 2013 Mar; 25 Suppl 2():S1-12. PubMed ID: 23388840
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Temsirolimus has activity in non-mantle cell non-Hodgkin's lymphoma subtypes: The University of Chicago phase II consortium.
    Smith SM; van Besien K; Karrison T; Dancey J; McLaughlin P; Younes A; Smith S; Stiff P; Lester E; Modi S; Doyle LA; Vokes EE; Pro B
    J Clin Oncol; 2010 Nov; 28(31):4740-6. PubMed ID: 20837940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial.
    Trněný M; Lamy T; Walewski J; Belada D; Mayer J; Radford J; Jurczak W; Morschhauser F; Alexeeva J; Rule S; Afanasyev B; Kaplanov K; Thyss A; Kuzmin A; Voloshin S; Kuliczkowski K; Giza A; Milpied N; Stelitano C; Marks R; Trümper L; Biyukov T; Patturajan M; Bravo MC; Arcaini L;
    Lancet Oncol; 2016 Mar; 17(3):319-331. PubMed ID: 26899778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.
    Goy A; Sinha R; Williams ME; Kalayoglu Besisik S; Drach J; Ramchandren R; Zhang L; Cicero S; Fu T; Witzig TE
    J Clin Oncol; 2013 Oct; 31(29):3688-95. PubMed ID: 24002500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical activity of everolimus in relapsed/refractory marginal zone B-cell lymphomas: results of a phase II study of the International Extranodal Lymphoma Study Group.
    Conconi A; Raderer M; Franceschetti S; Devizzi L; Ferreri AJ; Magagnoli M; Arcaini L; Zinzani PL; Martinelli G; Vitolo U; Kiesewetter B; Porro E; Stathis A; Gaidano G; Cavalli F; Zucca E
    Br J Haematol; 2014 Jul; 166(1):69-76. PubMed ID: 24673512
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Everolimus for patients with mantle cell lymphoma refractory to or intolerant of bortezomib: multicentre, single-arm, phase 2 study.
    Wang M; Popplewell LL; Collins RH; Winter JN; Goy A; Kaminski MS; Bartlett NL; Johnston PB; Lister J; Fanning SR; Tuscano JM; Beck JT; Kaya H; Robeva A; Fan J; Klimovsky J; Cheung W; Cherfi A; O'Connor OA
    Br J Haematol; 2014 May; 165(4):510-8. PubMed ID: 24579926
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I trial of rituximab, cladribine, and temsirolimus (RCT) for initial therapy of mantle cell lymphoma.
    Inwards DJ; Fishkin PA; LaPlant BR; Drake MT; Kurtin PJ; Nikcevich DA; Wender DB; Lair BS; Witzig TE
    Ann Oncol; 2014 Oct; 25(10):2020-2024. PubMed ID: 25057177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase 2 Study of Daratumumab in Relapsed/Refractory Mantle-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma.
    Salles G; Gopal AK; Minnema MC; Wakamiya K; Feng H; Schecter JM; Wang M
    Clin Lymphoma Myeloma Leuk; 2019 May; 19(5):275-284. PubMed ID: 30795996
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Temsirolimus and mantle cell lymphoma. Highly toxic, limited efficacy.
    Prescrire Int; 2010 Dec; 19(111):276-8. PubMed ID: 21355378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Matching-adjusted Indirect Comparisons of the Efficacy and Safety of Acalabrutinib Versus Other Targeted Therapies in Relapsed/Refractory Mantle Cell Lymphoma.
    Telford C; Kabadi SM; Abhyankar S; Song J; Signorovitch J; Zhao J; Yao Z
    Clin Ther; 2019 Nov; 41(11):2357-2379.e1. PubMed ID: 31699438
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results.
    Wang ML; Blum KA; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Zhang L; Baher L; Cheng M; Lee D; Beaupre DM; Rule S
    Blood; 2015 Aug; 126(6):739-45. PubMed ID: 26059948
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.